Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Lawsuit Delays OTC Nasacort Generic Competition

This article was originally published in The Pink Sheet Daily

Executive Summary

Sanofi says with Nasacort Allergy 24HR available at retailers nationwide and online, the firm withdrew its litigation against FDA, which appears to have slowed development of private-label equivalents.

You may also be interested in...



Sanofi's Consumer Health Q2 Results Ride Emerging Markets Boost

French pharma's worldwide OTC drug and other consumer health product sales grow 4.1% to $1.3bn led by more than 10% growth in its emerging markets, but US sales fell nearly 6% partly due to market-share incursion by private label OTCs.

Sanofi's Consumer Health Q2 Results Ride Emerging Markets Boost

French pharma's worldwide OTC drug and other consumer health product sales grow 4.1% to $1.3bn led by more than 10% growth in its emerging markets, but US sales fell nearly 6% partly due to market-share incursion by private label OTCs.

Sanofi Sues FDA To Stop Publication Of Nasacort Labeling Before Launch

After FDA denied Sanofi three years of market exclusivity for OTC Nasacort, the firm filed suit against the agency not to publish the product’s labeling prior to the launch. If successful, the firm could postpone the launch of generic competition.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel